CLINICAL TRIAL HIGHLIGHTS - DYSKINESIA.
作者信息
McFarthing Kevin, Prakash Neha, Simuni Tanya
机构信息
Parkinson's advocate, Innovation Fixer Ltd, Oxford, UK.
Parkinson's Disease and Movement Disorders Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
出版信息
J Parkinsons Dis. 2019;9(3):449-465. doi: 10.3233/JPD-199002.
Abstract
摘要
相似文献
1
CLINICAL TRIAL HIGHLIGHTS - DYSKINESIA.临床试验要点 - 运动障碍
J Parkinsons Dis. 2019;9(3):449-465. doi: 10.3233/JPD-199002.
2
Motor fluctuations and dyskinesia in Parkinson's disease.帕金森病中的运动波动和异动症
Parkinsonism Relat Disord. 2001 Oct;8(2):101-8. doi: 10.1016/s1353-8020(01)00024-4.
3
A unified dyskinesias rating scale for L-dopa-induced dyskinesias?左旋多巴诱发异动症的统一异动症评定量表？
Mov Disord. 1999;14 Suppl 1:74.
4
Rating scales for dyskinesias in Parkinson's disease.帕金森病异动症的评定量表。
Mov Disord. 1999;14 Suppl 1:48-53.
5
Hemiparkinsonism and levodopa-induced dyskinesias following focal nigral lesion.局灶性黑质损伤后的偏侧帕金森综合征和左旋多巴诱发的异动症
Mov Disord. 2006 Dec;21(12):2267-8; author reply 2268. doi: 10.1002/mds.21167.
6
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).多中心、开放标签的司立吉林治疗帕金森病左旋多巴诱导异动症患者的试验（SPLENDID研究）
Clin Neuropharmacol. 2004 Mar-Apr;27(2):58-62. doi: 10.1097/00002826-200403000-00003.
7
Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease.利鲁唑用于治疗晚期帕金森病中左旋多巴诱发的异动症。
Lancet. 1999 May 22;353(9166):1764-5. doi: 10.1016/S0140-6736(99)00120-8.
8
Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice.帕金森病左旋多巴使用中的常见误区：临床试验误导临床实践之时。
JAMA Neurol. 2017 Jun 1;74(6):633-634. doi: 10.1001/jamaneurol.2017.0348.
9
[Physiopathology of the dyskinesias induced by L-dopa].[左旋多巴诱发的运动障碍的病理生理学]
Rev Neurol. 1997 Aug;25 Suppl 2:S151-6.
10
The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.帕金森病中左旋多巴诱发异动症的现象学
Mov Disord. 1999;14 Suppl 1:13-8.
引用本文的文献
1
Misfolding and aggregation in neurodegenerative diseases: protein quality control machinery as potential therapeutic clearance pathways.神经退行性疾病中的错误折叠和聚集：蛋白质质量控制机制作为潜在的治疗性清除途径。
Cell Commun Signal. 2024 Aug 30;22(1):421. doi: 10.1186/s12964-024-01791-8.
2
Grid cells: the missing link in understanding Parkinson's disease?网格细胞：理解帕金森病的缺失环节？
Front Neurosci. 2024 Feb 8;18:1276714. doi: 10.3389/fnins.2024.1276714. eCollection 2024.
3
Targeting Striatal Glutamate and Phosphodiesterases to Control L-DOPA-Induced Dyskinesia.靶向纹状体谷氨酸和磷酸二酯酶以控制左旋多巴诱导的运动障碍。
Cells. 2023 Nov 30;12(23):2754. doi: 10.3390/cells12232754.
4
Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders.针对西格玛受体治疗神经退行性和神经发育障碍。
CNS Drugs. 2023 May;37(5):399-440. doi: 10.1007/s40263-023-01007-6. Epub 2023 May 11.
5
An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.帕金森病运动和非运动症状的非多巴胺能治疗方法的最新进展。
Curr Neuropharmacol. 2023;21(8):1806-1826. doi: 10.2174/1570159X20666220222150811.
6
Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis.普里多吡啶可修饰肌萎缩侧索硬化症 SOD1 小鼠模型的疾病表型。
Eur J Neurosci. 2022 Mar;55(5):1356-1372. doi: 10.1111/ejn.15608. Epub 2022 Feb 12.
7
The effect of 5-HT receptor agonists on the entopeduncular nucleus is modified in 6-hydroxydopamine-lesioned rats.5-HT 受体激动剂对损毁单侧黑质纹状体通路大鼠动眼神经核的影响。
Br J Pharmacol. 2021 Jun;178(12):2516-2532. doi: 10.1111/bph.15437. Epub 2021 May 6.
8
Parkinson's Disease Multimodal Complex Treatment (PD-MCT): Analysis of Therapeutic Effects and Predictors for Improvement.帕金森病多模式综合治疗（PD-MCT）：治疗效果分析及改善的预测因素
J Clin Med. 2020 Jun 16;9(6):1874. doi: 10.3390/jcm9061874.
本文引用的文献
1
Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.全天每隔 30 分钟的异动症和关期发生率，以及异动症和关期每日发作的评估：从 Gocovri 关键性试验日记数据的新分析。
J Parkinsons Dis. 2019;9(3):591-600. doi: 10.3233/JPD-181565.
2
Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease.普里多吡啶通过 sigma-1 受体在帕金森病小鼠模型中诱导功能神经恢复。
Neurotherapeutics. 2019 Apr;16(2):465-479. doi: 10.1007/s13311-018-00699-9.
3
Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.普里多宾，一种已临床应用的化合物，可减少帕金森病猴模型中 3,4-二羟基苯丙氨酸引起的运动障碍。
Mov Disord. 2019 May;34(5):708-716. doi: 10.1002/mds.27565. Epub 2018 Dec 21.
4
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.普里多宾在亨廷顿病患者中的安全性和疗效（PRIDE-HD）：一项 2 期、随机、安慰剂对照、多中心、剂量范围研究。
Lancet Neurol. 2019 Feb;18(2):165-176. doi: 10.1016/S1474-4422(18)30391-0. Epub 2018 Dec 15.
5
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts.左旋多巴诱导的帕金森病运动障碍：当前和不断发展的概念。
Ann Neurol. 2018 Dec;84(6):797-811. doi: 10.1002/ana.25364. Epub 2018 Nov 30.
6
Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial.萘丁美酮治疗晚期帕金森病：一项急性 L-DOPA 挑战的随机对照试验。
Parkinsonism Relat Disord. 2019 Mar;60:51-56. doi: 10.1016/j.parkreldis.2018.10.005. Epub 2018 Oct 4.
7
Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia.ADDS-5102（金刚烷胺）缓释胶囊每日睡前一次给药治疗运动障碍的药代动力学。
Clin Pharmacokinet. 2019 Jan;58(1):77-88. doi: 10.1007/s40262-018-0663-4.
8
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).ADDS-5102（金刚烷胺）控释胶囊治疗帕金森病左旋多巴诱导运动障碍的随机、安慰剂对照试验（EASE LID 3）。
Mov Disord. 2017 Dec;32(12):1701-1709. doi: 10.1002/mds.27131. Epub 2017 Aug 21.
9
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.用于帕金森病左旋多巴诱导异动症的ADS-5102（金刚烷胺）缓释胶囊（EASE LID研究）：一项随机临床试验。
JAMA Neurol. 2017 Aug 1;74(8):941-949. doi: 10.1001/jamaneurol.2017.0943.
10
A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.新型 mGluR5 负变构调节剂 Dipraglurant 治疗帕金森病左旋多巴诱导运动障碍的 2A 期临床试验。
Mov Disord. 2016 Sep;31(9):1373-80. doi: 10.1002/mds.26659. Epub 2016 May 23.
Zotero 插件